• 700 Atrium Drive, Suite A, Somerset, NJ 08873
  • (855) 581-9688
  • customerservice@solcohealthcare.com
logo
  • About
  • Products
  • Partner with Solco
  • Careers
  • News
  • Contact
  • About
  • Products
  • Partner with Solco
  • Careers
  • News
  • Contact

2017

  • Home
  •  
  • 2017
    • AUGUST 21, 2017
    • 0 COMMENTS
    Solco Healthcare US Announces the Approval of Generic Cymbalta® Capsules

    Solco Healthcare US Announces the Approval of Generic Cymbalta® Capsules

    CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Cymbalta® Capsules (Duloxetine delayed-release capsules), 20mg, 30mg and 60mg.  The product is available now. Duloxetine is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety

    Read more
    • admin
    • 2017,
    • Solco News
    • JUNE 9, 2017
    • 0 COMMENTS
    Solco Healthcare US Receives FDA Approval for Telmisartan Tablets, 20mg, 40mg and 80mg

    Solco Healthcare US Receives FDA Approval for Telmisartan Tablets, 20mg, 40mg and 80mg

    CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Telmisartan tablets, 20mg, 40mg and 80mg, which are AB-rated equivalents to Micardis® by Boehringer Ingelheim. “This recent approval continues to support Solco’s ability to provide high quality, cost effective medications to those in need,” said Hai Wang, President of Solco Healthcare. Telmisartan tablets

    Read more
    • admin
    • 2017,
    • Solco News
    • APRIL 24, 2017
    • 0 COMMENTS
    SOLCO HEALTHCARE INTRODUCES OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE Tablets

    SOLCO HEALTHCARE INTRODUCES OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE Tablets

    CRANBURY, NJ — Solco Healthcare today announced the launch of generic version of Daiichi-Sankyo’s Benicar-HCT®, Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20mg/12.5mg, 40/12.5mg and 40mg/25mg.  Solco received its final approval by the U.S. FDA for its abbreviated New Drug Application (ANDA) via its parent company Prinston Pharmaceutical Inc. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for

    Read more
    • admin
    • 2017,
    • Solco News

Press Release Archives

  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • Recall Information
  • Solco News
© 2019 Solco Healthcare. All Rights Reserved.
  • Product Catalog